Evidence map›Paper›PMID 38601687›Full record

ArticleHeliyon2024

Identification of a prognosis-related gene signature and ceRNA regulatory networks in lung adenocarcinoma.

Hong Wei, Fei Teng, XiaoLei Wang, XiuJuan Hou, HongBo Wang, Hong Wang, Hui Sun, XianLi Zhou

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hong WeiIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
Fei TengIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
XiaoLei WangIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
XiuJuan HouIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
HongBo WangIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
Hong WangIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
Hui SunIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
XianLi ZhouIn-Patient Ultrasound Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150081, China.
Harbin Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ceRNA network, consisting of both noncoding RNA and protein-coding RNA, governs the occurrence, progression, metastasis, and infiltration of lung adenocarcinoma. Signatures comprising multiple genes can effectively determine survival stratification and prognosis of patients with lung adenocarcinoma. To explore the mechanisms of lung adenocarcinoma progression and identify potential biological targets, we carried out systematic bioinformatics analyses of the genetic profiles of lung adenocarcinoma, such as weighted gene co-expression network analysis (WGCNA), differential expression (DE) assessment, univariate and multivariate Cox proportional hazard regression models, ceRNA modulatory networks generated using the ENCORI and miRcode databases, nomogram models, ROC curve assessment, and Kaplan-Meier survival curve analysis. The ceRNA network encompassed 37 nodes, comprising 12 mRNAs, 22 lncRNAs, and three miRNAs. Simultaneously, we performed integration analysis using the 12 genes from the ceRNA network. Our findings revealed that the signature established by these 12 genes serves as an adverse element in lung adenocarcinoma, contributing to unfavorable patient prognosis. To ensure the credibility of our results, we used in vitro experiments for further verification. In conclusion, our study delved into the potential mechanisms underlying lung adenocarcinoma via the ceRNA regulatory network, specifically focusing on the PIF1 and has-miR-125a-5p axis. Additionally, a signature comprising 12 genes was identified as a biomarker related to the prognosis of lung adenocarcinoma.

Indexed as

BiomarkerceRNALung adenocarcinomaSignatureWGCNA

Identifiers

PMID38601687
PMCPMC11004716
OpenAlexW4393409092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.